Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2985 - ARCAD-NADEGE cohort: Result of a small bowel adenocarcinomas prospective cohort


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Tumour Site

Gastrointestinal Cancers


Thomas Aparicio


Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282


T. Aparicio1, S. Manfredi2, D. Tougeron3, J. Henriques4, O. Bouche5, D. Pezet6, G. Piessen7, R. Coriat8, A. Zaanan9, J.L. Legoux10, E. Terrebone11, M. Pocard12, J. Gornet13, D. Vernerey4, P. Afchain14

Author affiliations

  • 1 Gastroenterology And Digestive Oncology, Hôpital Saint Louis, 75010 - Paris/FR
  • 2 Gastroenterology, CHU de Dijon, Dijon/FR
  • 3 Gastroenterology, CHU Poitiers, Jean Bernard Hôpital, 86021 - Poitiers/FR
  • 4 Statistics, CHU Besançon, Hôpital Jean Minjoz, Besançon/FR
  • 5 Gastroenterology, CHU de Reims - Hôpital Robert Debré, 51092 - Reims/FR
  • 6 Surgery, CHU de Clermont Ferrand, Clermont ferrand/FR
  • 7 Digestive Surgery, C.H.U. Claude Huriez, 59037 - Lille/FR
  • 8 Gastroenterology, Hôpital Cochin, 75679 - Paris/FR
  • 9 Gastroenterology And Digestive Oncology, Hopital European George Pompidou, 75015 - Paris/FR
  • 10 Hepato-gastroenterolgy And Digestive Oncology, C.H.R. Orleans - La Source, 45100 - Orleans/FR
  • 11 Gastroenterology, CHU Haut Lévèque, Pessac/FR
  • 12 Surgery, CHU Lariboisière, 75010 - Paris/FR
  • 13 Gastroenterology And Digestive Oncology, Hôpital St. Louis, 75010 - Paris/FR
  • 14 Oncology, CHU Saint Antoine, Paris/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2985


Small bowel adenocarcinoma (SBA) is a rare tumour. Data are coming from register study or monocentric retrospective studies. The purpose of the NADEGE cohort is to describe characteristics and prognosis of SBA in unselected patients (pts) at a nationwide level.


All the pts with a SBA diagnosed from January 2009 to December 2012 were enrolled in the NADEGE cohort. The study involved 74 centres that enrolled 347 eligible pts.


Pts were predominantly male (59%), median age: 63 years [23-90]. Primary locations were duodenum (60.6%), jejunum (20.7%) and ileum (18.7%). The tumour was poorly differentiated (20.9%), moderately (38.6%), well differentiated (40.5%) and not determined (7.5%). A predisposing disease was reported in 68 (19.7%) cases: Crohn disease 30 (8.6%), Lynch syndrome 24 (6.9%), familial adenomatous polyposis (FAP) 6 (1.8%), celiac disease 6 (1.8%) and Peutz-Jeghers syndrome 2 (0.6%). The tumour was metastatic at diagnostic in 122 (35.2%) pts, localized and resected in 202 (58.2%) and locally advanced in 19 (5.5%). Crohn disease was significantly associated with younger age, poor differentiation and ileum primary and Lynch syndrome with younger age, poor differentiation, early stage and duodenal primary. Adjuvant chemotherapy was performed in 61.5% pts with locally resected tumour mainly with oxaliplatin based regimen (89.9%). Palliative chemotherapy was performed in 85.1% of pts with metastases mainly with oxaliplatin based regimen (69.8%). With a median follow-up of 54 months, the 5 years overall survival (OS) rate was 87%, 78% and 55% for stage I, II, III respectively and the median survival was 12.7 months for stage IV. In pts with resected tumour multivariate analysis revealed a higher risk of death associated to poor differentiation (HR = 1.85, 95%CI 1.01-3.39, p = 0.047) and T4 (HR = 2.51, 95%CI 1.45-4.36, p = 0.001). Stage IV pts treated by chemotherapy had a better survival than pts not treated (14.3 vs 2.2 months, p = 0.0002).


NADEGE cohort provide data on SBA treated in a recent period. Tumours characteristics differ according to predisposing disease. FOLFOX chemotherapy is the main regimen used in adjuvant and metastatic setting. Tumour grade and T stage are prognostic factors for OS in resected tumour.

Clinical trial identification

Legal entity responsible for the study




Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.